Drug Profile
Research programme: Liposomal cytotoxic compounds - GP Pharm
Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator GP Pharm
- Class Alkaloids; Anthracyclines; Antineoplastics; Camptothecins; Deoxyribonucleosides; Doxorubicins; Pyrimidine nucleosides; Small molecules; Taxanes
- Mechanism of Action DNA intercalators; DNA synthesis inhibitors; Mitosis inhibitors; Tubulin modulators; Tubulin polymerisation promoters; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 29 Aug 2023 Preclinical development is ongoing Spain (GP Pharma website, August 2023)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Cancer in Spain (Parenteral)
- 22 Jan 2016 Preclinical trials in Cancer in Spain (parenteral) before January 2016